Keywords: اینفیلیکسیماب; Ulcerative colitis; Crohn's disease; Infliximab; Loss of response; Adsorptive granulocyte/monocyte apheresis; CD; Crohn's disease; CRP; C-reactive protein; GMA; granulocyte/monocyte apheresis; IL; interleukin; LOR; loss of response; TI; trough inflixi
مقالات ISI اینفیلیکسیماب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: اینفیلیکسیماب; Fructose; Infliximab; Tocilizumab; Blood pressure; Insulin resistance;
Keywords: اینفیلیکسیماب; Inflammatory Myofibroblastic Tumor; Liver transplant; Ulcerative colitis; Infliximab; Tumor necrosis factor alpha;
Keywords: اینفیلیکسیماب; Inflammatory bowel disease; Ulcerative colitis; Biological therapy; Biosimilar; Infliximab; Adalimumab; CT-P13; Switching;
Keywords: اینفیلیکسیماب; Crohn's disease; Infliximab; Perianal fistula; Biologics; TNF-α; Tumor necrosis factor α; CDAI; Crohn's disease activity index; PDAI; Perianal Crohn's disease activity index; BMI; Body mass index; 5-ASA; Aminosalicylates; IQR; Interquartile range;
Keywords: اینفیلیکسیماب; AZA; azathioprine; ADA; adalimumab; CYA; cyclosporine A; CYX; cyclophosphamide; ETN; etanercept; FK; tacrolimus; IFX; infliximab; IS; immunosuppressant; LFM; leflunomide; MMF; mycophenolate mofetil; MTX; methotrexate; RTX; rituximab; TAK; Takayasu's Arter
Keywords: اینفیلیکسیماب; Inflammation; Cytokines; Mood disorders; Major depressive disorder (MDD); Treatment; Infliximab;
Keywords: اینفیلیکسیماب; Infliximab; Neonate; Immunization; Rotavirus; HiB; Haemophilus influenzae B; PIANO; Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes; TNF; tumor necrosis factor;
Keywords: اینفیلیکسیماب; Inflammatory bowel disease; Colectomy; Immunosuppressive agents; nieswoiste zapalenie jelita; kolektomia; leki immunosupresyjne; ECCO; European Crohn's and Colitis Organisation; ESPGHAN; European Society for Peadiatric Gastroenterology, Hepatology and Nut
Keywords: اینفیلیکسیماب; Inflammatory bowel diseases; Epidemiology; Ulcerative rectocolitis; Crohn's disease; Infliximab; Doenças inflamatórias intestinais; Epidemiologia; Retocolite ulcerativa; Doença de Crohn; Infliximabe;
Keywords: اینفیلیکسیماب; Adalimumab; Anti-TNF; Crohn's disease; Fistulae; Infliximab; Stenosis;
Keywords: اینفیلیکسیماب; Infliximab; Biosimilar; TNF-α; Rheumatoid arthritis; anti-TNF-α; Therapeutic mAb;
Keywords: اینفیلیکسیماب; Cogan's syndrome; Treatment; Infliximab; Outcome;
Keywords: اینفیلیکسیماب; abatacept; antibodies; arthritis; hospital costs; humanized; infliximab; monoclonal; rheumatoid; rituximab;
Keywords: اینفیلیکسیماب; TNF Inhibitor; IBD Treatment; Patient Management; Inflammation; ADA; adalimumab; CD; Crohn's disease; IBD; inflammatory bowel disease; IFX; infliximab; IM; immunomodulator; IQR; interquartile range; TNF; tumor necrosis factor; UC; ulcerative colitis;
Keywords: اینفیلیکسیماب; MTX; methotrexate; TNF; tumor necrosis factor; IL; interleukin; CTLA4; cytotoxic T-lymphocyte antigen 4; IFX; infliximab; ADA; adalimumab; GLM; golimumab; CZP; certolizumab pegol; ETN; etanercept; TCZ; tocilizumab; ABA; abatacept; RTX; rituximab; UTK; ust
Keywords: اینفیلیکسیماب; Perianal Crohn's disease; Anal fistula; Anal abscess; Infliximab;
Keywords: اینفیلیکسیماب; ADA; adalimumab; AEs; adverse events; AZA; azathioprine; CI; confidence interval; Cy; cyclosporine; CNS; central nervous system; CS; corticosteroids; CYC; cyclophosphamide; CZP; certolizumab pegol; ePOST; Extrapulmonary Physician Organ Severity Tool; ETN;
Keywords: اینفیلیکسیماب; Bone sarcoidosis; Infliximab; Methotrexate; Bone marrow;
Keywords: اینفیلیکسیماب; Pediatric surgery; Pediatric gastroenterology; Crohn's disease; Infliximab; Surgical recurrence;
Keywords: اینفیلیکسیماب; Adjunctive therapies; Refractory Kawasaki disease; Intravenous immunoglobulin resistance; Glucocorticoids; Infliximab; Anakinra; Cyclosporin; Atorvastatin;
Keywords: اینفیلیکسیماب; Inflammatory bowel disease; Infliximab; Therapeutic drug monitoring;
Keywords: اینفیلیکسیماب; Acute severe ulcerative colitis; Colectomy rate; Cyclosporine; Immunosuppressive drugs; Infliximab;
Keywords: اینفیلیکسیماب; Anti-TNF therapy; Infliximab; Colonic anastomosis; Sepsis; Inflammatory bowel disease;
Keywords: اینفیلیکسیماب; Anticorps; biothérapies; calprotectine fécale; maladie de Crohn; maladies inflammatoires; chroniques intestinales; rectocolite hémorragique; Antibodies; biotherapy; fecal calprotectin; Crohn's disease; intestinal inflammatory disease; ulcerative coliti
Keywords: اینفیلیکسیماب; Adalimumab; Infliximab; Etarnecept; Ustekinumab; Psoriasis; Drugs therapies; Polymorphisms; Effectiveness;
Keywords: اینفیلیکسیماب; Bipolar depression; Inflammation; Innate immune system; NAC; NSAIDs; Infliximab; Minocycline; Antiinflammatory;
Keywords: اینفیلیکسیماب; biologic; cyclosporine; immunosuppressant; methotrexate; perioperative; psoriasis; psoriatic arthritis; tumor necrosis factor-alfa inhibitor; CI; confidence interval; IBD; inflammatory bowel disease; IFX; infliximab; IL; interleukin; MeSH; medical subject
Keywords: اینفیلیکسیماب; Biosimilar; Extrapolation; Inflammatory Bowel Disease; CT-P13; Infliximab; Infliximab-dyyb; ADA; anti-drug antibody; ADCC; antibody-dependent cell cytotoxicity; AS; ankylosing spondylitis; CD; Crohn's disease; CRP; C-reactive protein; EMA; European Medi
Keywords: اینفیلیکسیماب; Crohn's disease; Biologic therapy; Adalumimab; Infliximab; South Asian; European; Discrimination;
Keywords: اینفیلیکسیماب; Psoriasis; Biosimilar; Biologic; Clinical trials; Interchangeability; Substitution; Legislation; Infliximab; Etanercept; AdalimumabPsoriasis; Biosimilar; Biológico; Ensayos clínicos; Intercambiabilidad; Sustitución; Legislación; Infliximab; Etanercept; Ad
Keywords: اینفیلیکسیماب; RA; rheumatoid arthritis; IFX; infliximab; ETN; etanercept; ADCC; antibody-dependent cellular cytotoxicity; CDC; complement-dependent cytotoxicity; CCP; cyclic citrullinated peptide; RF; rheumatoid factor; MMP-3; matrix-metalloproteinase-3; DAS28-ESR; dis
Keywords: اینفیلیکسیماب; Pulmonary toxicity; Methotrexate; Infliximab; Tumor necrosis factor alpha; Endothelin-1Toxicidad pulmonar; Metotrexato; Infliximab; Factor de necrosis tumoral-alfa; Endotelina-1
Keywords: اینفیلیکسیماب; acne inversa; adalimumab; anakinra; biologics; etanercept; hidradenitis suppurativa; infliximab; treatment; tumor necrosis factor–alfa; ustekinumab
Keywords: اینفیلیکسیماب; Ulcerative Colitis; Infliximab; Accelerated Induction; AD; accelerated dosing; ASUC; acute severe ulcerative colitis; CRP; C-reactive protein; IBD; inflammatory bowel disease; IFX; infliximab; IQR; interquartile range; SD; standard dosing; TNF; tumor necr
Keywords: اینفیلیکسیماب; Drug; Response To Therapy; Prognostic Factor; Biomarker; ACT; Active Ulcerative Colitis Trials; ASCA; anti-Saccharomyces cerevisiae antibodies; ASUC; acute severe ulcerative colitis; CI; confidence interval; CRP; C-reactive protein level; CS; corticostero
Keywords: اینفیلیکسیماب; Cytokines; C-reactive protein; Tumor necrosis factor; Depression; Infliximab; Sleep; Polysomnography;
Keywords: اینفیلیکسیماب; Terapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; UstekinumabBiologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: اینفیلیکسیماب; Biologic therapy; Dose reduction; Adalimumab; Etanercept; Infliximab; UstekinumabTerapia biológica; Reducción de dosis; Adalimumab; Etanercept; Infliximab; Ustekinumab
Keywords: اینفیلیکسیماب; Adalimumab; Golimumab; Infliximab; Ulcerative colitis
Keywords: اینفیلیکسیماب; adalimumab; biologics; etanercept; infliximab; monitoring; psoriasis; psoriatic arthritis; safety; screening; ustekinumab; AAD; American Academy of Dermatology; ALP; alkaline phosphatase; ALT; alanine transaminase; ANA; antinuclear antibody; AST; aspartat
Keywords: اینفیلیکسیماب; Cytokines; Mood disorders; Inflammation; Anti-inflammatory agents; TNF-alpha; Infliximab;
Keywords: اینفیلیکسیماب; Biologics; Dermatology; Etanercept; Adalimumab; Infliximab; Ustekinumab; Secukinumab; IVIG;
Keywords: اینفیلیکسیماب; Infliximab; Systematic review; Meta-analysis; Rheumatoid arthritis; EfficacyInfliximabe; Revisão sistemática; Metanálise; Artrite reumatoide; Eficácia
Keywords: اینفیلیکسیماب; Thiopurines; Infliximab; Adalimumab; Surgery; Hospitalization; Infection; CD; Crohn's disease; CI; confidence interval; HR; hazard ratio; TNF; tumor necrosis factor;
Keywords: اینفیلیکسیماب; Psoriasis; Clinical equivalence; Meta-analysis; Biologic agents; Infliximab; Ustekinumab; Adalimumab; EtanerceptPsoriasis; Equivalencia clínica; Metaanálisis; Biológicos; Infliximab; Ustekinumab; Adalimumab; Etanercept
Keywords: اینفیلیکسیماب; Biosimilar; Extrapolation; Tumor necrosis factor alpha; Infliximab; Authorization; Safety
Keywords: اینفیلیکسیماب; Clinical practice; Clinical remission; Histological healing; Infliximab; Mucosal healing; Ulcerative colitis
Keywords: اینفیلیکسیماب; biologics; Crohn's Disease; disease pathogenesis; epidemiology; epigenetics; infliximab; Paediatric Inflammatory Bowel Disease; Ulcerative Colitis
Keywords: اینفیلیکسیماب; Crohn's disease; Infliximab; Adalimumab; Perianal fistula; AgeDoença de Crohn; Infliximabe; Adalimumabe; Fístula perianal; Idade